

SN5-27 and three variants thereof, (9Gln-SN5-27, l5Asn-SN5-21 and 9Gln-l5Asn-5N5-27). 15-Lys-SN has also been described in the art (Gardener et al, 1979) . Haffer et al (1991) describe eight secretin variants with reduced peptide bonds (the -CONH- bond being replaced by -CH2-HN-) between one of the eight N-terminal peptide bonds. Robberecht et al (1988) describe secretin fragments 2-27, 3-27, 5-27 and 7-27 and observed activity for secreting receptors. Konig et al (1986) exchanged the N-terminal 5 amino acids of a secretin for the N-terminal pentapeptide sequence of human somatotropin releasing factor to provide l-Tyr-2,4-diAla-5-Ile-SN, which showed secretin activity. Other active variants made were 3-L-Cystic acid-SN, 6-D-Phe-SN, 5-Allo-Thr-SN, and l-Cys-6-Cys-SN.--

Insert the attached Sequence Listing after the claims pages.

REMARKS

Reconsideration is requested.

The specification has been amended to include the attached Sequence Listing in response to the Notice to Comply dated October 22, 2001. The attached paper and computer-readable copies of the Sequence Listing are the same.

No new matter has been added.

An early and favorable Action on the merits is requested.